Omega Therapeutics Inc Quick Ratio (OMGA) starting from the third quarter 2024 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Omega Therapeutics Inc   (NASDAQ: OMGA)

Omega Therapeutics Inc 's Quick Ratio

OMGA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2024, Quick Ratio deteriorated to 1.26 a new company low.

Within Biotechnology & Pharmaceuticals industry 116 other companies have achieved higher Quick Ratio than Omega Therapeutics Inc in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 1135 to 1441.

Explain Quick Ratio?
How much Cash & cash equivalents OMGA´s has?
What are OMGA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OMGA Quick Ratio (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3
Y / Y Current Liabilities Change -9.86 % -24.11 % 36.32 % 22.05 % 82.45 %
Y / Y Cash & cash equivalent Change -65.98 % -59.42 % -56.11 % -41.11 % -39.8 %
Quick Ratio MRQ 1.26 1.8 2.43 2.74 3.33
OMGA's Total Ranking # 1441 # 1135 # 947 # 944 # 755
Seq. Current Liabilities Change -5.36 % 3.5 % -7.93 % -0.04 % -20.32 %
Seq. Cash & cash equivalent Change -33.75 % -23.62 % -18.24 % -17.77 % -20.96 %



Quick Ratio third quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 117
Healthcare Sector # 596
Overall Market # 1441


Quick Ratio Statistics
High Average Low
18.8 7.95 1.26
(Dec 31 2021)   (Sep 30 2024)




Financial Statements
Omega Therapeutics Inc 's Current Liabilities $ 24 Millions Visit OMGA's Balance sheet
Omega Therapeutics Inc 's Cash & cash equivalent $ 30 Millions Visit OMGA's Balance sheet
Source of OMGA's Sales Visit OMGA's Sales by Geography


Cumulative Omega Therapeutics Inc 's Quick Ratio

OMGA's Quick Ratio for the trailling 12 Months

OMGA Quick Ratio

 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth 0.66 % 17.44 % 63.75 % 65.12 % 86.74 %
Y / Y Cash & cash equivalent TTM Growth -54.78 % -48.62 % -42.46 % -36.29 % -38.01 %
Quick Ratio TTM 2.07 2.59 3 3.91 4.61
Total Ranking TTM # 3381 # 3237 # 3218 # 3249 # 2645
Seq. Current Liabilities TTM Growth -2.55 % -7.25 % 6.24 % 4.82 % 13.7 %
Seq. Cash & cash equivalent TTM Growth -21.94 % -19.99 % -18.61 % -11.05 % -11.29 %

Quick ratio ranking by company, industry and sector >> Back to OMGA Financial Strength Comparisons >> Go to Compare OMGA Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in OMGA's Current Liabilities to $24.17 millions, cumulative Quick Ratio to 2.07 below the OMGA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 150 other companies have achieved higher Quick Ratio than Omega Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 3237 to 3381.

Explain Quick Ratio?
How much Cash & cash equivalents OMGA´s has?
What are OMGA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 151
Healthcare Sector # 918
Within the Market # 3381


trailing twelve months Quick Ratio Statistics
High Average Low
15.6 8.09 2.07
(Jun 30 2022)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2024 MRQ Cash & cash equivalentSep 30 2024 MRQ Current Liabilities
Sab Biotherapeutics Inc   3.45 $ 30.401  Millions$ 8.816  Millions
Immunocore Holdings Plc  3.40 $ 901.282  Millions$ 265.152  Millions
Turnstone Biologics Corp   3.33 $ 45.400  Millions$ 13.644  Millions
Relay Therapeutics Inc   3.24 $ 152.357  Millions$ 46.968  Millions
Alector Inc   3.21 $ 457.202  Millions$ 142.525  Millions
Poseida Therapeutics Inc   3.20 $ 230.852  Millions$ 72.184  Millions
Moderna Inc   3.12 $ 6,867.000  Millions$ 2,201.000  Millions
Bioatla Inc   3.10 $ 56.516  Millions$ 18.211  Millions
Alpha Cognition Inc.  3.03 $ 7.333  Millions$ 2.422  Millions
Exelixis Inc   3.02 $ 1,189.161  Millions$ 394.346  Millions
Palisade Bio Inc   3.00 $ 8.040  Millions$ 2.681  Millions
Sutro Biopharma Inc   2.96 $ 388.254  Millions$ 131.291  Millions
Cidara Therapeutics Inc   2.87 $ 127.386  Millions$ 44.339  Millions
Neurocrine Biosciences Inc   2.86 $ 1,228.000  Millions$ 429.700  Millions
Adaptive Biotechnologies Corporation  2.78 $ 243.329  Millions$ 87.627  Millions
Biomx Inc  2.63 $ 23.537  Millions$ 8.944  Millions
Regenxbio Inc   2.49 $ 255.460  Millions$ 102.725  Millions
Leonabio Inc   2.48 $ 68.856  Millions$ 27.751  Millions
Vericel Corporation  2.46 $ 101.734  Millions$ 41.346  Millions
Ocugen Inc   2.46 $ 38.696  Millions$ 15.762  Millions
Inmune Bio Inc   2.43 $ 33.552  Millions$ 13.823  Millions
Lineage Cell Therapeutics Inc   2.36 $ 32.711  Millions$ 13.864  Millions
Exscientia Plc  2.30 $ 203.595  Millions$ 88.354  Millions
Argenx Se  2.24 $ 1,499.936  Millions$ 669.916  Millions
Biocryst Pharmaceuticals Inc   2.15 $ 330.826  Millions$ 153.567  Millions
Immunitybio inc   2.14 $ 130.367  Millions$ 60.960  Millions
Tarsus Pharmaceuticals Inc   2.14 $ 140.742  Millions$ 65.868  Millions
In8bio Inc   2.10 $ 4.001  Millions$ 1.906  Millions
Meiragtx Holdings Plc  2.07 $ 122.873  Millions$ 59.418  Millions
Enzo Biochem Inc  2.04 $ 47.735  Millions$ 23.397  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.